低剂量CT筛查肺癌:美国预防服务工作组更新证据报告与系统综述
该系统综述纳入223篇文献,评估低剂量CT(LDCT)筛查肺癌的效果。NLST和NELSON两大随机对照试验显示LDCT可降低高危吸烟人群的肺癌死亡率,但筛查也带来假阳性、过度诊断等危害。多数研究未采用现行结节评估方案。
要点
- 高危吸烟人群LDCT筛查可降低肺癌死亡率,NLST的IRR为0.85,NELSON为0.75。
- 筛查危害包括假阳性导致有创操作、过度诊断、 incidental findings及辐射诱发癌症。
- 多数研究未采用现行结节评估方案,可能低估减少假阳性的潜力。
核心结论
- 高危人群LDCT筛查可降低肺癌死亡率,但伴随假阳性、过度诊断等危害。
主要发现
- NLST:55-74岁高危吸烟者每年LDCT筛查3轮 vs 胸片,肺癌死亡率IRR 0.85(95%CI 0.75-0.96),NNS 323(6.5年随访)。
- NELSON:50-74岁高危吸烟者LDCT筛查4轮(间隔递增)vs 不筛查,肺癌死亡率IRR 0.75(95%CI 0.61-0.90),NNS 130(10年随访)。
- NLST每1000人筛查,假阳性导致17例有创操作(NNH 59),少于1人发生主要并发症。
- 过度诊断估计变异大(0%-67%), incidental findings常见(4.4%-40.7%)。
关键数值与推荐
- NLST:肺癌死亡率IRR 0.85(95%CI 0.75-0.96),NNS 323(6.5年)。
- NELSON:肺癌死亡率IRR 0.75(95%CI 0.61-0.90),NNS 130(10年)。
- NLST假阳性有创操作:每1000人17例,NNH 59。
- 过度诊断率0%-67%, incidental findings发生率4.4%-40.7%。
临床怎么用
- 对高危吸烟人群可考虑LDCT筛查以降低肺癌死亡率,需权衡假阳性及过度诊断风险。
- 应采用现行结节评估方案以减少假阳性导致的有创操作。
局限性
- 试验人群较美国筛查合格人群更可能获益(如基于预期寿命)。
- 多数研究未使用现行结节评估方案,可能高估假阳性危害。
- 过度诊断和 incidental findings估计变异大,数据未合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lung cancer is the leading cause of cancer-related death in the US. OBJECTIVE: To review the evidence on screening for lung cancer with low-dose computed tomography (LDCT) to inform the US Preventive Services Task Force (USPSTF). DATA SOURCES: MEDLINE, Cochrane Library, and trial registries through May 2019; references; experts; and literature surveillance through November 20, 2020. STUDY SELECTION: English-language studies of screening with LDCT, accuracy of LDCT, risk prediction models, or treatment for early-stage lung cancer. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings. Data were not pooled because of heterogeneity of populations and screening protocols. MAIN OUTCOMES AND MEASURES: Lung cancer incidence, lung cancer mortality, all-cause mortality, test accuracy, and harms. RESULTS: This review included 223 publications. Seven randomized clinical trials (RCTs) (N = 86 486) evaluated lung cancer screening with LDCT; the National Lung Screening Trial (NLST, N = 53 454) and Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON, N = 15 792) were the largest RCTs. Participants were more likely to benefit than the US screening-eligible population (eg, based on life expectancy). The NLST found a reduction in lung cancer mortality (incidence rate ratio [IRR], 0.85 [95% CI, 0.75-0.96]; number needed to screen [NNS] to prevent 1 lung cancer death, 323 over 6.5 years of follow-up) with 3 rounds of annual LDCT screening compared with chest radiograph for high-risk current and former smokers aged 55 to 74 years. NELSON found a reduction in lung cancer mortality (IRR, 0.75 [95% CI, 0.61-0.90]; NNS to prevent 1 lung cancer death of 130 over 10 years of follow-up) with 4 rounds of LDCT screening with increasing intervals compared with no screening for high-risk current and former smokers aged 50 to 74 years. Harms of screening included radiation-induced cancer, false-positive results leading to unnecessary tests and invasive procedures, overdiagnosis, incidental findings, and increases in distress. For every 1000 persons screened in the NLST, false-positive results led to 17 invasive procedures (number needed to harm, 59) and fewer than 1 person having a major complication. Overdiagnosis estimates varied greatly (0%-67% chance that a lung cancer was overdiagnosed). Incidental findings were common, and estimates varied widely (4.4%-40.7% of persons screened). CONCLUSIONS AND RELEVANCE: Screening high-risk persons with LDCT can reduce lung cancer mortality but also causes false-positive results leading to unnecessary tests and invasive procedures, overdiagnosis, incidental findings, increases in distress, and, rarely, radiation-induced cancers. Most studies reviewed did not use current nodule evaluation protocols, which might reduce false-positive results and invasive procedures for false-positive results.
引用
- Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 33687468. doi:10.1001/jama.2021.0377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。